Grunwald Thomas, Pedersen Finn Skou, Wagner Ralf, Uberla Klaus
Department of Molecular and Medical Virology, Ruhr-University Bochum, Bochum, Germany.
J Gene Med. 2004 Feb;6(2):147-54. doi: 10.1002/jgm.479.
Human gene therapy vectors based on primate lentiviruses harbour in contrast to oncoretroviruses the risk of vector mobilization by human immunodeficiency viruses (HIV). Infection of cells transduced with a lentiviral vector by HIV could lead to packaging of the lentiviral vector RNA into HIV particles and transfer of the vector.
A new approach based on primer complementation was developed to reduce the risk of vector mobilization. The primer binding site (PBS) of an SIV-based vector was mutated abolishing tRNA primer binding and thus blocking reverse transcription. This block was efficiently by-passed during vector production by providing an artificial tRNA matching the mutated PBS with titers reaching 10(6) infectious units/ml.
Primer-complemented SIV vectors were mobilized from transduced cells by HIV-1 >150-fold less efficiently than vectors with wild-type PBS. Mobilization of the primer-complemented SIV vector by SIV was inhibited to a lesser extent indicating reduced efficacy of the primer complementation approach for preventing mobilization of lentiviral vectors by homologous virus. The analysis of the PBS of the vector DNA in target cells transduced with vectors containing mutated PBS in the absence of a matched tRNA suggests that formation of heterozygous particles followed by priming on the helper RNA and strand switch during reverse transcription can lead to mobilization of the primer-complemented vector by SIV, but not HIV-1. Although self-inactivating vectors were more efficient in preventing vector mobilization by HIV-1 than primer-complemented vectors, mobilization remained undectable only if both approaches were combined.
The primer complementation approach should further reduce the risk of mobilization of self-inactivating SIV-based vectors by HIV-1 and thus increase their safety.
与嗜肝DNA病毒相比,基于灵长类慢病毒的人类基因治疗载体存在被人类免疫缺陷病毒(HIV)动员载体的风险。HIV感染用慢病毒载体转导的细胞可能导致慢病毒载体RNA包装到HIV颗粒中并转移载体。
开发了一种基于引物互补的新方法来降低载体动员的风险。基于SIV的载体的引物结合位点(PBS)发生突变,消除了tRNA引物结合,从而阻断逆转录。在载体生产过程中,通过提供与突变PBS匹配的人工tRNA,有效地绕过了这一阻断,滴度达到10(6) 感染单位/毫升。
与具有野生型PBS的载体相比,HIV-1从转导细胞中动员引物互补的SIV载体的效率低150倍以上。SIV对引物互补的SIV载体的动员抑制程度较小,表明引物互补方法在预防同源病毒动员慢病毒载体方面的效果降低。在用不含匹配tRNA的突变PBS载体转导的靶细胞中分析载体DNA的PBS表明,杂合颗粒的形成,随后在辅助RNA上引发和逆转录过程中的链转换,可导致SIV而非HIV-1动员引物互补载体。虽然自我失活载体在预防HIV-1动员载体方面比引物互补载体更有效,但只有将两种方法结合起来,动员才仍然无法检测到。
引物互补方法应进一步降低HIV-1动员基于SIV的自我失活载体的风险,从而提高其安全性。